Full-Time

Vice President

Finance

Confirmed live in the last 24 hours

Voyager Therapeutics

Voyager Therapeutics

201-500 employees

Develops genetic medicines for neurological diseases

Biotechnology
Healthcare

Senior, Expert

Lexington, MA, USA

Category
Corporate Finance
Finance & Banking
Requirements
  • 12+ years of finance/accounting experience including financial reporting in a SOX-compliant public company
  • Solid track record as a manager, including experience managing, evaluating and developing top talent, and success building a strong team that supports operations and business growth
  • Success in building an effective financial function in a high growth biotech or life sciences environment, including work implementing 'best practice' policies and processes related to financial operations and reporting
  • Working knowledge of drug development process within the biotech/pharmaceutical industry, including clinical trial accruals is required
  • Very strong analytical skills and technical accounting capabilities
  • Strong organizational skills combined with ability strong initiative and drive are critical
  • Demonstrated strength in presenting and communicating financial information
  • Track record of building strong cross-functional relationships and partnerships both within internal company teams, and with external alliance and collaborator partners
Responsibilities
  • Improve, enhance and manage the internal reporting processes of the company, including establishment of key performance measures, analyses of results and internal management reporting to support all external reporting requirements and to improve and enhance the overall management of the business.
  • Lead and develop a team of Finance professionals.
  • Manage all internal and external (SEC) reporting and compliance.
  • Oversee timely and efficient monthly and quarterly closing process, in support of meeting internal and external reporting and data needs
  • Lead ongoing utilization and implementation of current ERP and other financial systems, manage development of reporting and dashboards utilizing key system data to benefit financial management of Voyager’s business.
  • Strategic oversight and driver of improvements to various processes including procure to pay, financial reporting, etc. leading the team to efficiencies and improvements
  • Oversee equity plan administration, stock plan system and all trading compliance and required disclosures
  • Management of the auditor relationship with EY, and supervision of all cyclical audit processes for financial reporting, SOX and other.
  • Manage presentations and reporting review for the Audit Committee of the Board of Directors
  • Oversee cash management and act as company treasurer
  • Monitor and assess the impact on the company of emerging accounting and reporting regulations and guidance
  • Manage business insurance requirements, including broker selection, coverage requirements, policies and selection
  • Provide technical accounting and financial leadership, including input, oversight and guidance on polices and projects.
  • Evaluate transactions contemplated by Voyager to assess financial and accounting impact.
  • Evaluate, select and manage a variety of business partners and vendors who serve the needs of the Voyager organization.
  • Oversee tax filings, planning and compliance

Voyager Therapeutics develops genetic medicines aimed at treating neurological diseases, particularly those affecting the central nervous system like amyotrophic lateral sclerosis (ALS). Their approach involves using a proprietary AAV (adeno-associated virus) capsid discovery platform, which allows for the delivery of genetic material directly to the brain through intravenous dosing. This method addresses the challenge of crossing the blood-brain barrier, which is crucial for effective treatment of brain-related conditions. Unlike many competitors, Voyager Therapeutics emphasizes collaboration with larger pharmaceutical companies to enhance their research and development efforts, which helps them accelerate the commercialization of their therapies. The company's goal is to create meaningful treatments that improve the lives of patients suffering from severe neurological conditions.

Company Stage

IPO

Total Funding

$102.1M

Headquarters

Cambridge, Massachusetts

Founded

2014

Growth & Insights
Headcount

6 month growth

3%

1 year growth

11%

2 year growth

49%
Simplify Jobs

Simplify's Take

What believers are saying

  • Voyager's recent $100 million upfront payment from Novartis highlights strong financial backing and potential for rapid growth.
  • The appointment of experienced executives like Nathan Jorgensen as CFO and Toby Ferguson as CMO strengthens the company's leadership team.
  • The selection of a development candidate for the GBA1 program in collaboration with Neurocrine Biosciences demonstrates the productivity and potential of their partnerships.

What critics are saying

  • The highly specialized focus on neurological diseases may limit market opportunities compared to broader biotech firms.
  • Dependence on partnerships and milestone payments introduces financial uncertainty if collaborations do not yield expected results.

What makes Voyager Therapeutics unique

  • Voyager Therapeutics leverages its proprietary AAV capsid discovery platform to deliver genetic material directly to the brain, a significant advancement over traditional methods.
  • The company's focus on crossing the blood-brain barrier addresses a critical challenge in treating neurological diseases, setting it apart from many competitors.
  • Voyager's strong emphasis on collaborative partnerships with major pharmaceutical companies like Novartis accelerates its R&D and commercialization efforts.

Help us improve and share your feedback! Did you find this helpful?